APA (7th ed.) Citation

Thatcher, N., & Thomas, M. (2016). Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC). Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw382.10

Chicago Style (17th ed.) Citation

Thatcher, Nicholas, and Michael Thomas. "Secondary Efficacy Results from a Phase 3 Study Comparing Efficacy and Safety of Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw382.10.

MLA (9th ed.) Citation

Thatcher, Nicholas, and Michael Thomas. "Secondary Efficacy Results from a Phase 3 Study Comparing Efficacy and Safety of Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw382.10.